C4X Discovery preparing to do something 'very different' in drug development

Published on 14th Nov 2017

Clive Dix, chief executive of C4X Discovery Holdings plc, (LON:C4XD) brings Proactive up to speed on developments with the firm's portfolio of drug candidates.

They've recently presented some pre-clinical data at a leading industry conference which they say strengthens the evidence base backing the potential of the anti-addiction drug Orexin-1.

It's being developed to target the craving process and therefore is expected to be used across a broad range of substance disorders.

The latest study assessed nicotine self-administration and cue-induced reinstatement; the latter is where strong cravings are triggered by an object or ritual closely associated with taking an addictive substance.

Pharma & Biotech
Add to favorites
Share with:

Related Videos

Latest

Real Estate Holding & Development
Carillion fighting for survival after third profit warning

Carillion fighting for survival after third profit warning

Published on 17th Nov 2017
Pharma & Biotech
Small cap spotlight: Advanced Onco, Midwich Group and Prairie Mining

Small cap spotlight: Advanced Onco, Midwich Group and Prairie Mining

Published on 17th Nov 2017

Recommended videos

Real Estate Holding & Development
Carillion fighting for survival after third profit warning

Carillion fighting for survival after third profit warning

Published on 17th Nov 2017
Mining
Arizona Silver encouraged by latest Ramsay drill assays

Arizona Silver encouraged by latest Ramsay drill assays

Published on 17th Nov 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082.
You can contact us here.

Choose Proactive Region: